Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 204514, 9 pages
http://dx.doi.org/10.1155/2008/204514
Review Article

Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors

1Department of Neurology, University of Bonn, Sigmund-Freud-Street 25, 53105 Bonn, Germany
2Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener street 34, 50931 Cologne, Germany

Received 1 March 2008; Revised 29 May 2008; Accepted 24 June 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Lars Tatenhorst et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Reviews of Cell & Developmental Biology, vol. 12, pp. 335–363, 1996. View at Publisher · View at Google Scholar · View at PubMed
  2. M. Robinson-Rechavi, A.-S. Carpentier, M. Duffraisse, and V. Laudet, “How many nuclear hormone receptors are there in the human genome?,” Trends in Genetics, vol. 17, no. 10, pp. 554–556, 2001. View at Publisher · View at Google Scholar
  3. L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar
  4. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  5. H. Escriva, F. Delaunay, and V. Laudet, “Ligand binding and nuclear receptor evolution,” BioEssays, vol. 22, no. 8, pp. 717–727, 2000. View at Publisher · View at Google Scholar
  6. S. Kersten and W. Wahli, “Peroxisome proliferator activated receptor agonists,” EXS, vol. 89, pp. 141–151, 2000. View at Google Scholar
  7. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. L. Michalik, J. Auwerx, J. P. Berger et al., “International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. T. M. Willson, M. H. Lambert, and S. A. Kliewer, “Peroxisome proliferator-activated receptor γ and metabolic disease,” Annual Review of Biochemistry, vol. 70, pp. 341–367, 2001. View at Publisher · View at Google Scholar · View at PubMed
  10. G. D. Barish, “Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity,” The Journal of Nutrition, vol. 136, no. 3, pp. 690–694, 2006. View at Google Scholar
  11. G. Krey, O. Braissant, F. L'Horset et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997. View at Publisher · View at Google Scholar
  12. A. Bernardo and L. Minghetti, “PPAR-γ agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, pp. 93–109, 2006. View at Publisher · View at Google Scholar
  13. A. Cimini, L. Cristiano, S. Colafarina et al., “PPARγ-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF),” International Journal of Cancer, vol. 117, no. 6, pp. 923–933, 2005. View at Publisher · View at Google Scholar · View at PubMed
  14. M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo,” The Journal of Neuroscience, vol. 20, no. 18, pp. 6862–6867, 2000. View at Google Scholar
  15. N. C. Inestrosa, J. A. Godoy, R. A. Quintanilla, C. S. Koenig, and M. Bronfman, “Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling,” Experimental Cell Research, vol. 304, no. 1, pp. 91–104, 2005. View at Publisher · View at Google Scholar · View at PubMed
  16. K. S. Park, R. D. Lee, S.-K. Kang et al., “Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway,” Experimental Cell Research, vol. 297, no. 2, pp. 424–433, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. S. A. Smith, G. R. Monteith, J. A. Robinson, N. G. Venkata, F. J. May, and S. J. Roberts-Thomson, “Effect of the peroxisome proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons,” Journal of Neuroscience Research, vol. 77, no. 2, pp. 240–249, 2004. View at Publisher · View at Google Scholar · View at PubMed
  18. S. Moreno, S. Farioli-Vecchioli, and M. P. Cerù, “Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS,” Neuroscience, vol. 123, no. 1, pp. 131–145, 2004. View at Publisher · View at Google Scholar
  19. J. W. Woods, M. Tanen, D. J. Figueroa et al., “Localization of PPARδ in murine central nervous system: expression in oligodendrocytes and neurons,” Brain Research, vol. 975, no. 1-2, pp. 10–21, 2003. View at Publisher · View at Google Scholar
  20. A. Cimini, L. Cristiano, A. Bernardo, S. Farioli-Vecchioli, S. Stefanini, and M. P. Cerù, “Presence and inducibility of peroxisomes in a human glioblastoma cell line,” Biochimica et Biophysica Acta, vol. 1474, no. 3, pp. 397–409, 2000. View at Publisher · View at Google Scholar
  21. I. Saluja, J. G. Granneman, and R. P. Skoff, “PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture,” Glia, vol. 33, no. 3, pp. 191–204, 2001. View at Publisher · View at Google Scholar
  22. L. Cristiano, A. Bernardo, and M. P. Cerù, “Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes,” Journal of Neurocytology, vol. 30, no. 8, pp. 671–683, 2001. View at Publisher · View at Google Scholar
  23. T. E. Cullingford, K. Bhakoo, S. Peuchen, C. T. Dolphin, R. Patel, and J. B. Clark, “Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system,” Journal of Neurochemistry, vol. 70, no. 4, pp. 1366–1375, 1998. View at Google Scholar
  24. S. Farioli-Vecchioli, S. Moreno, and M. P. Cerù, “Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system,” Journal of Neurocytology, vol. 30, no. 1, pp. 21–33, 2001. View at Publisher · View at Google Scholar
  25. S. S. T. Lee, T. Pineau, J. Drago et al., “Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators,” Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012–3022, 1995. View at Google Scholar
  26. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar
  27. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
  28. O. Braissant and W. Wahli, “Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development,” Endocrinology, vol. 139, no. 6, pp. 2748–2754, 1998. View at Publisher · View at Google Scholar
  29. S. Basu-Modak, O. Braissant, P. Escher, B. Desvergne, P. Honegger, and W. Wahli, “Peroxisome proliferator-activated receptor β regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures,” The Journal of Biological Chemistry, vol. 274, no. 50, pp. 35881–35888, 1999. View at Publisher · View at Google Scholar
  30. J. M. Peters, S. S. T. Lee, W. Li et al., “Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000. View at Publisher · View at Google Scholar
  31. J. Ehrmann, Jr., N. Vavrusová, Y. Collan, and Z. Kolár, “Peroxisome proliferator-activated receptors (PPARs) in health and disease,” Biomedical Papers, vol. 146, no. 2, pp. 11–14, 2002. View at Google Scholar
  32. P. Kleihues, D. N. Louis, B. W. Scheithauer et al., “The WHO classification of tumors of the nervous system,” Journal of Neuropathology & Experimental Neurology, vol. 61, no. 3, pp. 215–225, 2002. View at Google Scholar
  33. A. Behin, K. Hoang-Xuan, A. F. Carpentier, and J.-Y. Delattre, “Primary brain tumours in adults,” The Lancet, vol. 361, no. 9354, pp. 323–331, 2003. View at Publisher · View at Google Scholar · View at PubMed
  34. A. Giese, R. Bjerkvig, M. E. Berens, and M. Westphal, “Cost of migration: invasion of malignant gliomas and implications for treatment,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1624–1636, 2003. View at Publisher · View at Google Scholar · View at PubMed
  35. J. M. Pérez-Ortiz, P. Tranque, C. F. Vaquero et al., “Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-γ,” The Journal of Biological Chemistry, vol. 279, no. 10, pp. 8976–8985, 2004. View at Publisher · View at Google Scholar · View at PubMed
  36. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at PubMed
  37. K. Berge, K. J. Tronstad, E. N. Flindt et al., “Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways,” Carcinogenesis, vol. 22, no. 11, pp. 1747–1755, 2001. View at Publisher · View at Google Scholar
  38. N. Chattopadhyay, D. P. Singh, O. Heese et al., “Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARγ agonists as inducers of apoptosis,” Journal of Neuroscience Research, vol. 61, no. 1, pp. 67–74, 2000. View at Publisher · View at Google Scholar
  39. P. Collet, L. Domenjoud, M. D. Devignes, H. Murad, H. Schohn, and M. Dauça, “The human semaphorin 6B gene is down regulated by PPARs,” Genomics, vol. 83, no. 6, pp. 1141–1150, 2004. View at Publisher · View at Google Scholar · View at PubMed
  40. M. Maggiora, M. Bologna, M. P. Cerù et al., “An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines,” International Journal of Cancer, vol. 112, no. 6, pp. 909–919, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. M. G. Posch, C. Zang, W. Mueller, U. Lass, A. von Deimling, and E. Elstner, “Somatic mutations in peroxisome proliferator-activated receptor-γ are rare events in human cancer cells,” Medical Science Monitor, vol. 10, no. 8, pp. BR250–BR254, 2004. View at Google Scholar
  42. N. Strakova, J. Ehrmann, P. Dzubak, J. Bouchal, and Z. Kolar, “The synthetic ligand of peroxisome proliferator-activated receptor-γ ciglitazone affects human glioblastoma cell lines,” Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 3, pp. 1239–1247, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. T. Zander, J. A. Kraus, C. Grommes et al., “Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ,” Journal of Neurochemistry, vol. 81, no. 5, pp. 1052–1060, 2002. View at Publisher · View at Google Scholar
  44. C. Zang, M. Wächter, H. Liu et al., “Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas,” Journal of Neuro-Oncology, vol. 65, no. 2, pp. 107–118, 2003. View at Publisher · View at Google Scholar
  45. M. Kato, T. Nagaya, M. Fujieda, K. Saito, J. Yoshida, and H. Seo, “Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines,” Japanese Journal of Cancer Research, vol. 93, no. 6, pp. 660–666, 2002. View at Google Scholar
  46. R. Morosetti, T. Servidei, M. Mirabella et al., “The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines,” International Journal of Oncology, vol. 25, no. 2, pp. 493–502, 2004. View at Google Scholar
  47. N. Strakova, J. Ehrmann, J. Bartos, J. Malikova, J. Dolezel, and Z. Kolar, “Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors,” Neoplasma, vol. 52, no. 2, pp. 126–136, 2005. View at Google Scholar
  48. E. Benedetti, R. Galzio, B. Cinque et al., “Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARγ agonists,” Journal of Cellular Physiology. In press.
  49. J. M. Pérez-Ortiz, P. Tranque, M. Burgos, C. F. Vaquero, and J. Llopis, “Glitazones induce astroglioma cell death by releasing reactive oxygen species from mitochondria: modulation of cytotoxicity by nitric oxide,” Molecular Pharmacology, vol. 72, no. 2, pp. 407–417, 2007. View at Publisher · View at Google Scholar · View at PubMed
  50. D. W. Kang, C. H. Choi, J. Y. Park, S. K. Kang, and Y. K. Kim, “Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells,” Neurochemical Research, vol. 33, no. 3, pp. 551–561, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. C. Grommes, G. E. Landreth, U. Schlegel, and M. T. Heneka, “The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor γ ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 313, no. 2, pp. 806–813, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. C. Grommes, G. E. Landreth, M. Sastre et al., “Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment,” Molecular Pharmacology, vol. 70, no. 5, pp. 1524–1533, 2006. View at Publisher · View at Google Scholar · View at PubMed
  53. D. Sugiyama, H. Kusuhara, H. Taniguchi et al., “Functional characterization of rat brain specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine,” The Journal of Biological Chemistry, vol. 278, no. 44, pp. 43489–43495, 2003. View at Publisher · View at Google Scholar · View at PubMed
  54. A. Spagnolo, E. N. Grant, R. Glick, T. Lichtor, and D. L. Feinstein, “Differential effects of PPARγ agonists on the metabolic properties of gliomas and astrocytes,” Neuroscience Letters, vol. 417, no. 1, pp. 72–77, 2007. View at Publisher · View at Google Scholar · View at PubMed
  55. A. Spagnolo, R. P. Glick, H. Lin, E. P. Cohen, D. L. Feinstein, and T. Lichtor, “Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-γ thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts,” Journal of Neurosurgery, vol. 106, no. 2, pp. 299–305, 2007. View at Publisher · View at Google Scholar · View at PubMed
  56. R. Coras, A. Hölsken, S. Seufert et al., “The peroxisome proliferator-activated receptor-γ agonist troglitazone inhibits transforming growth factor-β-mediated glioma cell migration and brain invasion,” Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1745–1754, 2007. View at Publisher · View at Google Scholar · View at PubMed
  57. P. Prasanna, A. Thibault, L. Liu, and D. Samid, “Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells,” Journal of Neurochemistry, vol. 66, no. 2, pp. 710–716, 1996. View at Google Scholar
  58. C.-J. Yao, G.-M. Lai, C.-F. Chan, A.-L. Cheng, Y.-Y. Yang, and S.-E. Chuang, “Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone,” International Journal of Cancer, vol. 118, no. 3, pp. 773–779, 2006. View at Publisher · View at Google Scholar · View at PubMed
  59. D.-C. Liu, C.-B. Zang, H.-Y. Liu, K. Possinger, S.-G. Fan, and E. Elstner, “A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells,” Acta Pharmacologica Sinica, vol. 25, no. 10, pp. 1312–1319, 2004. View at Google Scholar
  60. S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,” Cancer Research, vol. 61, no. 16, pp. 6213–6218, 2001. View at Google Scholar
  61. C.-W. Shiau, C.-C. Yang, S. K. Kulp et al., “Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ,” Cancer Research, vol. 65, no. 4, pp. 1561–1569, 2005. View at Publisher · View at Google Scholar · View at PubMed
  62. Y. Akasaki, G. Liu, H. H. Matundan et al., “A peroxisome proliferator-activated receptor-γ agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells,” The Journal of Biological Chemistry, vol. 281, no. 10, pp. 6165–6174, 2006. View at Publisher · View at Google Scholar · View at PubMed
  63. K. Schultze, B. Böck, A. Eckert et al., “Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin,” Apoptosis, vol. 11, no. 9, pp. 1503–1512, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. D. Evans, W. A. Mann, J. de Heer et al., “Variation in the gene for human peroxisome proliferator activated receptor γ (PPARγ) does not play a major role in the development of morbid obesity,” International Journal of Obesity, vol. 24, no. 5, pp. 647–651, 2000. View at Publisher · View at Google Scholar
  65. W. M. Smith, X.-P. Zhou, K. Kurose et al., “Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases,” Human Genetics, vol. 109, no. 2, pp. 146–151, 2001. View at Publisher · View at Google Scholar
  66. X.-P. Zhou, W. M. Smith, O. Gimm et al., “Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population,” Journal of Medical Genetics, vol. 37, no. 6, pp. 410–414, 2000. View at Publisher · View at Google Scholar
  67. T. Servidei, R. Morosetti, C. Ferlini et al., “The cellular response to PPARγ ligands is related to the phenotype of neuroblastoma cell lines,” Oncology Research, vol. 14, no. 7-8, pp. 345–354, 2004. View at Google Scholar
  68. Y. Sato, H. Sasaki, Y. Kobayashi et al., “Expression of PPAR-gamma is correlated with the clinical course of neuroblastoma,” Journal of Pediatric Surgery, vol. 38, no. 2, pp. 205–210, 2003. View at Publisher · View at Google Scholar · View at PubMed
  69. S. W. Han, M. E. Greene, J. Pitts, R. K. Wada, and N. Sidell, “Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARγ) in human neuroblastoma cells,” Clinical Cancer Research, vol. 7, no. 1, pp. 98–104, 2001. View at Google Scholar
  70. S. Di Loreto, B. D'Angelo, M. A. D'Amico et al., “PPARβ agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y,” Journal of Cellular Physiology, vol. 211, no. 3, pp. 837–847, 2007. View at Publisher · View at Google Scholar · View at PubMed
  71. A. O. Isaac, I. Kawikova, A. L. M. Bothwell, C. K. Daniels, and J. C. K. Lai, “Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells,” Neurochemical Research, vol. 31, no. 11, pp. 1305–1316, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. A. Bonfigli, O. Zarivi, S. Colafarina et al., “Human glioblastoma ADF cells express tyrosinase, L-tyrosine hydroxylase and melanosomes and are sensitive to L-tyrosine and phenylthiourea,” Journal of Cellular Physiology, vol. 207, no. 3, pp. 675–682, 2006. View at Publisher · View at Google Scholar · View at PubMed
  73. G. C. Burdge, H. Rodway, J. A. Kohler, and K. A. Lillycrop, “Effect of fatty acid supplementation on growth and differentiation of human IMR-32 neuroblastoma cells in vitro,” Journal of Cellular Biochemistry, vol. 80, no. 2, pp. 266–273, 2000. View at Publisher · View at Google Scholar
  74. H. A. Rodway, A. N. Hunt, J. A. Kohler, A. D. Postle, and K. A. Lillycrop, “Lysophosphatidic acid attenuates the cytotoxic and degree of peroxisome proliferator-activated receptor γ activation induced by 15-deoxyΔ12,14-prostaglandin J2 in neuroblastoma cells,” Biochemical Journal, vol. 382, no. 1, pp. 83–91, 2004. View at Publisher · View at Google Scholar · View at PubMed
  75. V. C. Emmans, H. A. Rodway, A. N. Hunt, and K. A. Lillycrop, “Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression,” Biochemical Society Transactions, vol. 32, no. 5, pp. 840–842, 2004. View at Publisher · View at Google Scholar · View at PubMed
  76. E. J. Kim, K. S. Park, S. Y. Chung et al., “Peroxisome proliferator-activated receptor-γ activator 15-deoxy-Δ12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 2, pp. 505–517, 2003. View at Publisher · View at Google Scholar · View at PubMed
  77. A. Rossi, P. Kapahi, G. Natoli et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase,” Nature, vol. 403, no. 6765, pp. 103–118, 2000. View at Publisher · View at Google Scholar · View at PubMed
  78. U. Valentiner, M. Carlsson, R. Erttmann, H. Hildebrandt, and U. Schumacher, “Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro,” Toxicology, vol. 213, no. 1-2, pp. 157–168, 2005. View at Publisher · View at Google Scholar · View at PubMed
  79. I. Cellai, S. Benvenuti, P. Luciani et al., “Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells,” British Journal of Cancer, vol. 95, no. 7, pp. 879–888, 2006. View at Publisher · View at Google Scholar · View at PubMed
  80. T. W. Jung, J. Y. Lee, W. S. Shim et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity,” Biochemical and Biophysical Research Communications, vol. 340, no. 1, pp. 221–227, 2006. View at Publisher · View at Google Scholar · View at PubMed
  81. T. W. Jung, J. Y. Lee, W. S. Shim et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production,” Journal of the Neurological Sciences, vol. 253, no. 1-2, pp. 53–60, 2007. View at Publisher · View at Google Scholar · View at PubMed
  82. P. Hau, L. Kunz-Schughart, U. Bogdahn et al., “Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study,” Oncology, vol. 73, no. 1-2, pp. 21–25, 2008. View at Publisher · View at Google Scholar · View at PubMed